JDD Spotlight
The PROAK study evaluated real-world outcomes in patients with actinic keratosis reated with tirbanibulin 1% ointment over 24 weeks. Early improvements in quality of life were noted as soon as week 8, with both patients and clinicians reporting high satisfaction and stable treatment effectiveness over time. Safety and tolerability were favorable, with minimal adverse events reported. Discover how tirbanibulin is shaping patient care in actinic keratosis.
